44911-0027 NDC - MOLD ANTIGENS (ALTERNARIA TENUIS, ASPERGILLUS NIGER, CANDIDA ALBICANS, CANDIDA PARAPSILOSIS, MUCOR RACEMOSUS, PULLULARIA PULLULANS, RHIZOPUS NIGRICANS, TORULA CEREVISIAE, ARSENICUM ALBUM, PHOSPHORUS, PULSATILLA, SEPIA)

Drug Information

Product NDC: 44911-0027

Proprietary Name: Mold Antigens

Non Proprietary Name: Alternaria Tenuis, Aspergillus Niger, Candida Albicans, Candida Parapsilosis, Mucor Racemosus, Pullularia Pullulans, Rhizopus Nigricans, Torula Cerevisiae, Arsenicum Album, Phosphorus, Pulsatilla, Sepia

Active Ingredient(s):
  • 12 [hp_X]/mL ARSENIC TRIOXIDE;
  • 12 [hp_X]/mL PHOSPHORUS;
  • 12 [hp_X]/mL PULSATILLA VULGARIS;
  • 12 [hp_X]/mL SEPIA OFFICINALIS JUICE;
  • 12 [hp_X]/mL ALTERNARIA ALTERNATA;
  • 12 [hp_X]/mL ASPERGILLUS NIGER VAR. NIGER;
  • 12 [hp_X]/mL RHIZOPUS STOLONIFER;
  • 12 [hp_X]/mL MUCOR RACEMOSUS;
  • 12 [hp_X]/mL AUREOBASIDIUM PULLULANS VAR. PULLUTANS;
  • 12 [hp_X]/mL CANDIDA ALBICANS;
  • 12 [hp_X]/mL CANDIDA PARAPSILOSIS;
  • 12 [hp_X]/mL SACCHAROMYCES CEREVISIAE


Administration Route(s): ORAL

Dosage Form(s): LIQUID

Pharmacy Class(es):
  • Non-Standardized Fungal Allergenic Extract [EPC];
  • Increased Histamine Release [PE];
  • Cell-mediated Immunity [PE];
  • Increased IgG Production [PE];
  • Fungal Proteins [CS];
  • Allergens [CS];
  • Non-Standardized Fungal Allergenic Extract [EPC];
  • Increased Histamine Release [PE];
  • Cell-mediated Immunity [PE];
  • Increased IgG Production [PE];
  • Fungal Proteins [CS];
  • Allergens [CS];
  • Non-Standardized Fungal Allergenic Extract [EPC];
  • Increased Histamine Release [PE];
  • Cell-mediated Immunity [PE];
  • Increased IgG Production [PE];
  • Fungal Proteins [CS];
  • Allergens [CS];
  • Non-Standardized Fungal Allergenic Extract [EPC];
  • Increased Histamine Release [PE];
  • Cell-mediated Immunity [PE];
  • Increased IgG Production [PE];
  • Fungal Proteins [CS];
  • Allergens [CS];
  • Non-Standardized Fungal Allergenic Extract [EPC];
  • Increased Histamine Release [PE];
  • Cell-mediated Immunity [PE];
  • Increased IgG Production [PE];
  • Fungal Proteins [CS];
  • Allergens [CS];
  • Non-Standardized Fungal Allergenic Extract [EPC];
  • Increased Histamine Release [PE];
  • Cell-mediated Immunity [PE];
  • Increased IgG Production [PE];
  • Fungal Proteins [CS];
  • Allergens [CS];
  • Non-Standardized Fungal Allergenic Extract [EPC];
  • Increased Histamine Release [PE];
  • Cell-mediated Immunity [PE];
  • Increased IgG Production [PE];
  • Allergens [CS];
  • Fungal Proteins [CS];
  • Non-Standardized Fungal Allergenic Extract [EPC];
  • Non-Standardized Food Allergenic Extract [EPC];
  • Increased Histamine Release [PE];
  • Cell-mediated Immunity [PE];
  • Dietary Proteins [CS];
  • Allergens [CS];
  • Fungal Proteins [CS]

Labeler Information

Labeler Name: Energique, Inc.
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number:
Marketing Category: UNAPPROVED HOMEOPATHIC
Start Marketing Date:11/7/2012
End Marketing Date:8/30/2023

Package Information

No. Package Code Package Description Billing Unit
144911-0027-130 mL in 1 BOTTLE, DROPPER (44911-0027-1)

NDC Record

Field Name Field Value Definition
PRODUCT NDC44911-0027The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEMold AntigensThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEAlternaria Tenuis, Aspergillus Niger, Candida Albicans, Candida Parapsilosis, Mucor Racemosus, Pullularia Pullulans, Rhizopus Nigricans, Torula Cerevisiae, Arsenicum Album, Phosphorus, Pulsatilla, SepiaThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMELIQUIDThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE11/7/2012This is the date that the labeler indicates was the start of its marketing of the drug product.
END MARKETING DATE8/30/2023This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
MARKETING CATEGORY NAMEUNAPPROVED HOMEOPATHICProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
LABELER NAMEEnergique, Inc.Name of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEARSENIC TRIOXIDE; PHOSPHORUS; PULSATILLA VULGARIS; SEPIA OFFICINALIS JUICE; ALTERNARIA ALTERNATA; ASPERGILLUS NIGER VAR. NIGER; RHIZOPUS STOLONIFER; MUCOR RACEMOSUS; AUREOBASIDIUM PULLULANS VAR. PULLUTANS; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; SACCHAROMYCES CEREVISIAEThis is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH12; 12; 12; 12; 12; 12; 12; 12; 12; 12; 12; 12 
ACTIVE INGRED UNIT[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL 
PHARM CLASSESNon-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Allergens [CS],Fungal Proteins [CS],Non-Standardized Fungal Allergenic Extract [EPC],Non-Standardized Food Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Dietary Proteins [CS],Allergens [CS],Fungal Proteins [CS] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 9/11/2020